ArticleGene therapy2009
Herpes simplex virus vector-mediated delivery of neurturin rescues erectile dysfunction of cavernous nerve injury.
Article in Gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Emerging trends in virus and virus-like particle gene therapy delivery to the brain.Molecular therapy. Nucleic acids · 2024Review
- Potential Therapeutic Strategies and Substances for Facial Nerve Regeneration Based on Preclinical Studies.International journal of molecular sciences · 2021Review
- Herpes Simplex Virus: A Versatile Tool for Insights Into Evolution, Gene Delivery, and Tumor Immunotherapy.Virology : research and treatment · 2020Review
- Adipose-derived stem cells modified byNeural regeneration research · 2020Article
- The GDNF Family: A Role in Cancer?Neoplasia (New York, N.Y.) · 2018Review
- Neuroprotective and Nerve Regenerative Approaches for Treatment of Erectile Dysfunction after Cavernous Nerve Injury.International journal of molecular sciences · 2017Review
- Temporal changes in neurotrophic factors and neurite outgrowth in the major pelvic ganglion following cavernous nerve injury.Journal of neuroscience research · 2015Article
- Landmarks in erectile function recovery after radical prostatectomy.Nature reviews. Urology · 2015Review
- GGF2 is neuroprotective in a rat model of cavernous nerve injury-induced erectile dysfunction.The journal of sexual medicine · 2015Article
- Sonic Hedgehog regulates brain-derived neurotrophic factor in normal and regenerating cavernous nerves.The journal of sexual medicine · 2013Article
- Neurotrophin therapy improves recovery of the neuromuscular continence mechanism following simulated birth injury in rats.Neurourology and urodynamics · 2013Article
- Emerging tools for erectile dysfunction: a role for regenerative medicine.Nature reviews. Urology · 2012Review
- Emerging and novel therapeutic approaches in the treatment of male erectile dysfunction.Current urology reports · 2011Review
- Hepatocyte growth factor incorporated into herpes simplex virus vector accelerates facial nerve regeneration after crush injury.Gene therapy · 2011Article
- Regeneration of the cavernous nerve by Sonic hedgehog using aligned peptide amphiphile nanofibers.Biomaterials · 2011Article
- Erectile preservation following radical prostatectomy.Therapeutic advances in urology · 2011Article
- Gene therapy as future treatment of erectile dysfunction.Expert opinion on biological therapy · 2010Review
- Emerging gene and stem cell therapies for the treatment of erectile dysfunction.Nature reviews. Urology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Neurturin (NTN), a member of glial cell line-derived neurotrophic factor (GDNF) family, is known as an important neurotrophic factor for penis-projecting neurons. We recently demonstrated significant protection from erectile dysfunction (ED) following a replication-defective herpes simplex virus (HSV) vector-mediated GDNF delivery to the injured cavernous nerve. Herein, we applied HSV vector-mediated delivery of NTN to this ED model. Rat cavernous nerve was injured bilaterally using a clamp and dry ice. For HSV-treated groups, 20 microl of vector stock was administered directly to the damaged nerve. Delivery of an HSV vector expressing both green fluorescent protein and lacZ (HSV-LacZ) was used as a control. Intracavernous pressure along with systemic arterial pressure (ICP/AP) was measured 2 and 4 weeks after the nerve injury. Fluorogold (FG) was injected into the penile crus 7 days before being killed to assess neuronal survival. Four weeks after nerve injury, rats treated with HSV-NTN exhibited significantly higher ICP/AP compared with untreated or control vector-treated groups. The HSV-NTN group had more FG-positive major pelvic ganglion neurons than the control group following injury. HSV vector-mediated delivery of NTN could be a viable approach for the improvement of ED following cavernous nerve injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.